4.55
4.55 (0%)
As of Apr 17, 2025
Altimmune, Inc. [ALT]
Source:
Company Overview
ltimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic associated steatohepatitis (“MASH”).
| Country | United States |
| Headquarters | gaithersburg, maryland |
| Phone Number | (240) 654-1450 |
| Industry | manufacturing |
| CEO | Vipin K. Garg |
| Website | www.altimmune.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-103.2 |
| Net Income | $-95.1 |
| Net Cash | $-98.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -515,860 |
| Profit as % of Revenues | -0% |
| Profit as % of Assets | -54.3% |
| Profit as % of Stockholder Equity | -77% |
Management Effectiveness
| Return on Equity | -77% |
| Return on Assets | -68.2% |
| Turnover Ratio | 0% |
| EBITA | $-103.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $139.3 |
| Total Liabilities | $15.8 |
| Operating Cash Flow | $-79.8 |
| Investing Cash Flow | $-28.4 |
| Financing Cash Flow | $10 |
